Stimulation of human immunodeficiency virus type 1 (HIV-1) specific cytolytic effector function using allogeneic cell immunotherapy

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1034858

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

A preventative HIV vaccine is not currently available. Stimulation of the bodies own immune cells (T-cells) may be associated with better protection against the virus, and we have recently discovered that T-cells already present in humans are frequently stimulated by foreign (allogeneic) cells. Therefore we aim to determine if “vaccination” with allogeneic cells could stimulate a HIV specific immune response in humans. These results could have important implications for HIV vaccine design.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2015

Funding Scheme: Project Grants

Funding Amount: $377,648.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

T cell immunotherapy | T cell memory | T cell receptor | human immunodeficiency virus (HIV) | human leukocyte antigen (HLA) | vaccine | vaccine development | viral immunity

Related Links